Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $73.6 million.

  • Celldex Therapeutics' Operating Expenses rose 3308.21% to $73.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.8 million, marking a year-over-year increase of 3162.2%. This contributed to the annual value of $202.1 million for FY2024, which is 2519.62% up from last year.
  • Celldex Therapeutics' Operating Expenses amounted to $73.6 million in Q3 2025, which was up 3308.21% from $64.6 million recorded in Q2 2025.
  • Celldex Therapeutics' 5-year Operating Expenses high stood at $73.6 million for Q3 2025, and its period low was $16.9 million during Q2 2021.
  • In the last 5 years, Celldex Therapeutics' Operating Expenses had a median value of $36.6 million in 2022 and averaged $39.9 million.
  • As far as peak fluctuations go, Celldex Therapeutics' Operating Expenses tumbled by 2762.72% in 2021, and later soared by 11606.97% in 2022.
  • Quarter analysis of 5 years shows Celldex Therapeutics' Operating Expenses stood at $20.7 million in 2021, then surged by 42.68% to $29.5 million in 2022, then soared by 75.46% to $51.8 million in 2023, then increased by 10.52% to $57.2 million in 2024, then increased by 28.7% to $73.6 million in 2025.
  • Its Operating Expenses was $73.6 million in Q3 2025, compared to $64.6 million in Q2 2025 and $63.4 million in Q1 2025.